drugset
Drugs / Luvadaxistat
last change Oct 2024 re-read 3 minutes ago

Luvadaxistat

also known as TAK-831 · NBI-1065844

Small molecule targets DAO via inhibition

Developed for
schizophrenia · Friedreich ataxia
Investigated by
Neurocrine Biosciences · Takeda

Trials 11

today NCT05182476 · Ph 2 NCT04234672 · Ph 1 NCT03706469 · Ph 1 NCT03687684 · Ph 1 NCT03359785 · Ph 2 NCT03382639 · Ph 2 NCT03214588 · Ph 2 NCT03224325 · Ph 1 NCT03101293 · Ph 1 NCT02716987 · Ph 1 NCT02566759 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT04234672 Feb → Apr 2020 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT03706469 Oct → Dec 2018 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT03687684 Oct 2018 → Jun 2019 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT03224325 Jul 2017 → Sep 2018 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT03101293 Apr → May 2017 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT02716987 Mar → Aug 2016 — Neurocrine Biosciences Completed No outcome recorded
Phase 1 NCT02566759 Sep 2015 → Jun 2016 — Neurocrine Biosciences Terminated No outcome recorded
Phase 24 trials · 4 missed
Phase 2 NCT05182476 Dec 2021 → Jun 2024 schizophrenia Neurocrine Biosciences Terminated Missed primary
Phase 2 NCT03359785 Jan 2018 → Dec 2020 schizophrenia Neurocrine Biosciences Completed Missed primary
Phase 2 NCT03382639 Jan 2018 → Dec 2020 schizophrenia Neurocrine Biosciences Completed Missed primary
Phase 2 NCT03214588 Nov 2017 → Dec 2018 Friedreich ataxia Neurocrine Biosciences Completed Missed primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as Luvadaxistat ClinicalTrials.gov intervention name — accepted as the source's own label NCT05182476 ↗
2

NCT03359785 ↗

NCT03382639 ↗
Known as NBI-1065844 “Luvadaxistat (TAK-831/NBI-1065844) is an investigational d-amino acid oxidase (DAAO) inhibitor that increases d-serine levels at NMDAR coagonist sites.” PMID 38943928 ↗ Jun 2024
Known as TAK-831 “Luvadaxistat (TAK-831/NBI-1065844) is an investigational d-amino acid oxidase (DAAO) inhibitor that increases d-serine levels at NMDAR coagonist sites.” PMID 38943928 ↗ Jun 2024
8

NCT03687684 ↗

NCT02716987 ↗

NCT04234672 ↗

NCT02566759 ↗

NCT03706469 ↗

NCT03214588 ↗

NCT03224325 ↗

NCT03101293 ↗
Action Inhibit “TAK-831 is a highly selective and potent inhibitor of DAO” NCT02716987 ↗
Modality Small molecule — CHEMBL2338801 ↗
Route Oral “TAK-831 oral suspension.” NCT02566759 ↗
Target DAO “TAK-831 is a highly selective and potent inhibitor of DAO” NCT02716987 ↗